Study Confirms or Refutes the Hypothesis That the Autologous Bone Marrow Concentrate Together With the Allograft is a Better Alternative for the Posterolateral Fusion in Spine Surgery Than the Allograft Alone
Spondyloarthrosis, Spondylosis
About this trial
This is an interventional treatment trial for Spondyloarthrosis, Spondylosis focused on measuring Lumbar spine, Posterolateral fusion, Allograft, Bone marrow concentrate, Mesenchymal stem cells, Fusion rate
Eligibility Criteria
Inclusion Criteria:
- degenerative disc disease or degenerative spondylolisthesis
Exclusion Criteria:
- vertebral fractures,
- infections or spinal neoplasms,
- non-rigid instrumentations,
- medication affecting bone mineralization (e.g., corticosteroids),
- body mass index higher than 35,
- systemic diseases,
- blood disease and/or immunosuppressant treatment and/or dicoumarol therapy;
- immunosuppressant and/or neoplastic and/or infectious diseases.
Sites / Locations
Arms of the Study
Arm 1
Experimental
bone marrow concentrate
In forty cases, the posterolateral fusion was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.